Alagramam, Kumar N
Gopal, Suhasini R http://orcid.org/0000-0002-3525-3222
Geng, Ruishuang
Chen, Daniel H-C
Nemet, Ina
Lee, Richard
Tian, Guilian
Miyagi, Masaru
Malagu, Karine F
Lock, Christopher J
Esmieu, William R K
Owens, Andrew P
Lindsay, Nicola A
Ouwehand, Krista
Albertus, Faywell
Fischer, David F
Bürli, Roland W
MacLeod, Angus M
Harte, William E
Palczewski, Krzysztof
Imanishi, Yoshikazu http://orcid.org/0000-0003-4696-4836
Article History
Received: 9 July 2015
Accepted: 8 March 2016
First Online: 25 April 2016
Competing interests
: Usher III Initiative contracted K.F.M., C.J.L., W.R.K.E., A.P.O., N.A.L., K.O., F.A., D.F.F., R.W.B. and A.M.M. from BioFocus to carry out hit-to-lead optimization of small molecules described in this report. W.E.H. serves as the director of pharmaceutical development for the Usher III Initiative and as chief translational officer for the School of Medicine at CWRU. W.E.H., R.W.B., K.F.M., C.J.L., W.R.K.E. and A.P.O. are named on patents WO 2014066835, WO 2014066836 and WO 2012148994. The mouse <i>Clrn1</i> cDNA used to generate transgenic mouse TgAC1 and the human ortholog are protected by provisional US patent 62/076,114 to K.N.A.